D
Avid Bioservices, Inc. CDMO
$6.83 $0.152.25%
Recommendation
Sell
Prev Close
$6.39
Volume
1,442,149
Avg Vol (90D)
1,473,642
Market Cap
$404.10M
Dividend & Yield
--
52-Week Range
$4.07 - $19.97
P/E (TTM)
--
EPS (TTM)
-$0.1814
My Lists My Alerts
Report
Rating
Reward
C-
Fair
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Fair
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
CDMO Stock Earnings: Avid Bioservices Misses EPS, Beats Revenue for Q3 2024
4/25/2024 - InvestorPlace
Avid Bioservices still sees FY24 revenue $137M-$147M, consensus $138.66M
4/24/2024 - The Fly
Avid Bioservices reports Q3 EPS (9c), consensus (5c)
4/24/2024 - The Fly
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
4/24/2024 - Globe Newswire
Laughing Water Capital - Avid Bioservices: A Few Years Away From Large, Relatively Sticky FCF
4/21/2024 - SeekingAlpha
Avid Bioservices (CDMO, $6.71) price exceeded its 50-day Moving Average on April 17, 2024
4/18/2024 - Tickeron - Stocks
Analysts' Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
4/16/2024 - TipRanks Financial Blog
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
4/12/2024 - PR Newswire
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities Hagens Berman
4/10/2024 - Globe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
4/8/2024 - Globe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
4/4/2024 - PR Newswire
Investigation into Avid Bioservices, Inc. Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to Know!
4/3/2024 - Globe Newswire
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities Hagens Berman
4/1/2024 - Globe Newswire
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
4/1/2024 - TipRanks Financial Blog
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
3/31/2024 - Globe Newswire
SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
3/28/2024 - Globe Newswire
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities Hagens Berman
3/28/2024 - Globe Newswire
Avid Bioservices (CDMO, $6.97) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 27, 2024
3/28/2024 - Tickeron - Stocks
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
3/27/2024 - PR Newswire
Avid Bioservices management to meet with Craig Hallum
3/27/2024 - The Fly
Avid Bioservices management to meet with Craig Hallum
3/25/2024 - The Fly
CDMO LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation CDMO
3/24/2024 - Globe Newswire
Avid Bioservices (CDMO, $6.86) entered Uptrend as Momentum indicator ascends above 0 level on Mar 21, 2024
3/22/2024 - Tickeron - Stocks
Avid Bioservices (CDMO, $6.86) price exceeded its 50-day Moving Average on March 21, 2024
3/22/2024 - Tickeron - Stocks
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities Hagens Berman
3/21/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$140.94M
EBITDA (TTM)
-$501.00K
EBIT (TTM)
-$9.74M
Net Income (TTM)
-$11.45M
Balance Sheet
Total Assets (Q)
$454.64M
Total Debt (Q)
$196.70M
Total Liabilities (Q)
$270.97M
Book Value Per Share (Q)
$2.90
Cash Flow
Cash from Operations (TTM)
$1.71M
Cash from Investing (TTM)
-$57.64M
Cash from Financing (TTM)
$9.72M
Net Change in Cash (TTM)
-$46.22M
Filings
Filing Date
Thursday, December 7, 2023
Period Date
Saturday, September 30, 2023
Next Filing
(est)
Price History
Loading...
Beta
1.20
7-Day Total Return
-3.26%
30-Day Total Return
0.31%
60-Day Total Return
-3.69%
90-Day Total Return
30.92%
Year to Date Total Return
2.52%
1-Year Total Return
-66.41%
2-Year Total Return
-61.07%
3-Year Total Return
-69.25%
5-Year Total Return
41.13%
52-week Low
Dec 08, 2023 - $4.07
52-week High
Apr 24, 2023 - $19.97
Valuation
Market Cap
$404.10M - Small Cap
Enterprise Value
$569.37M
Price/Sales (TTM)
2.86
Price/Book (Q)
2.20
Dividends and Shares
Shares Outstanding
63.15M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.avidbio.com
Phone Number
714-508-6100
Address
14191 Myford Road
Tustin, CA 92780
Country
United States
Year Founded
1981
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing... more
NASDAQ 04/24/2024 4:00PM Eastern Quotes delayed
Weiss Ratings